Jornal de Proteômica e Bioinformática
Acesso livre

Abstrato

Peptidomic Analysis via One-Step Direct Transfer Technology for Colorectal Cancer Biomarker Discovery

Kazuhiko Uchiyama, Yuji Naito, Nobuaki Yagi, Katsura Mizushima, Yasuki Higashimura, Yasuko Hirai, Tetsuya Okayama, Naohisa Yoshida, Kazuhiro Katada, Kazuhiro Kamada, Osamu Handa, Takeshi Ishikawa, Tomohisa Takagi, Hideyuki Konishi, Daisuke Nonaka, Kyoichi Asada, Lyang-Ja Lee, Kenji Tanaka, Yoshiaki Kuriu, Masayoshi Nakanishi, Eigo Otsuji and Yoshito

Colorectal cancer (CRC) is a major cause of cancer-related mortality worldwide. Early CRC diagnosis is critical, since patients diagnosed at an early stage have an increased five-year survival rate after surgical resection. Serum biomarkers for CRC detection have been described and peptidomic analysis is a promising approach because of its diagnostic potential. A total of 72 CRC patients and 63 healthy controls were investigated. We used a comprehensive peptide analysis technique, BLOTCHIP®-MS analysis, a combination of electrophoresis and mass spectrometry, for high sensitivity detection of trace amounts of serum peptides. The prediction model comprised five peptides: m/z 1616.66 (fibrinogen alpha chain), m/z 2390.26 (alpha-1-antitrypsin), m/z 2858.42 (AHSG S-cysteinylated form), m/z 3622.78 (VASP), and m/z 3949.98 (F. XIIIa). The three CRC groups, stages II to IV, II + IIIa, and IIIb + IV, were discriminated from controls. High diagnostic performance was suggested by AUC (0.924), sensitivity (83%), specificity (92%), and median probability ratio (6.80) to CRC stage II to IV. We describe a prediction model for CRC diagnosis using candidate biomarker peptides discovered by a one-step direct transfer technology (BLOTCHIP®-MS analysis). The high throughput technology has high reproducibility and is applicable for peptide quantification and differential analysis for biomarker discovery.